NCT02572635 - A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Pneumococcal Infection

Interventions

BIOLOGICAL

PnuBioVax

Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.

BIOLOGICAL

Placebo

Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.

Trial Locations (1)

Simbec Research Ltd, Merthyr Tydfil